Rhythm Pharmaceuticals (RYTM) Insider Mcgirr Sells 4,712 Shares

David McGirr sold 4,712 shares of Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM) on June 23, 2026. This transaction did not occur under a pre-arranged trading plan. The biotech firm focuses on treatments for rare neuroendocrine diseases and is currently trading at $107.55 per share as of Friday.

Other Institutional Activity in Rhythm Pharmaceuticals

RA Capital Management, L.P. holds a substantial position in Rhythm Pharmaceuticals, with 6,666,837 shares valued at approximately $579.8 million, showing no change in their holdings. BlackRock, Inc. trimmed its stake by 60,183 shares, now holding 6,237,151 shares worth about $542.4 million, a 1.0% decrease. Baker Bros. Advisors LP maintained its position with 5,604,483 shares valued at $487.4 million. Primecap Management Co/CA/ reduced its holdings by 61,160 shares, ending with 3,417,509 shares worth $297.2 million, a 1.8% decrease. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, holding 3,040,718 and 2,967,825 shares, respectively.

Rhythm Pharmaceuticals, Inc. Stock Up 10.8%

Shares of Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM) traded near $107.55 on Friday. The company has a market capitalization of approximately $6.95 billion and does not have a meaningful forward P/E ratio due to its lack of profitability. The stock's 52-week range is between $60.80 and $122.20, with a 50-day moving average of $88.36 and a 200-day moving average of $97.77. The company maintains a current ratio of 4.17 and a quick ratio of 3.63, with a debt-to-equity ratio of 47.26.

Recent Earnings

Rhythm Pharmaceuticals reported revenue of $217.2 million, with a growth rate of 83.8%. However, the company is not yet profitable, with a net margin of -93.3% and a return on equity of -101.2%. The next earnings report is scheduled for August 4, 2026.

Analysts Set New Price Targets

On June 16, 2026, Canaccord Genuity maintained its 'buy' rating with a price target of $151. Wells Fargo also maintained a 'buy' rating on June 15, 2026, with a target of $155. Overall, analysts have a consensus 'strong buy' rating for Rhythm Pharmaceuticals, with a mean target price of $139.47 based on 15 opinions.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, is a commercial-stage biopharmaceutical company. It focuses on rare neuroendocrine diseases, offering treatments like IMCIVREE for various obesity-related syndromes. The company is advancing through clinical trials with other promising candidates like bivamelagon and RM-718. Led by CEO Dr. David P. Meeker, the company employs 414 people.

Bottom Line

David McGirr's recent sale of Rhythm Pharmaceuticals shares reflects ongoing insider activity within the company. With a strong focus on rare disease treatments, the company continues to attract attention from institutional investors and analysts. As a biopharmaceutical firm, Rhythm Pharmaceuticals is a key player in the healthcare sector, though its lack of profitability remains a challenge. Investors should note that insider transactions like McGirr's are typically disclosed after the fact.